

SHARON REGIONAL HEALTH SYSTEM



*Advanced Care
Close to Home*

- Advanced Wound Recovery Center
- Behavioral Health Services
- Brain Attack/Stroke Center
- Breast Care Center
- Cancer Care Center
- Chest Pain Emergency Center
- Comprehensive Pain Management Center
- Corporate Health Services
- Diabetes Center
- Ear, Nose, Throat & Hearing Center
- Emergency Care Center
- Express Care
- Family Medicine Centers
- HealthPLACE
- Heart Institute
- Home Health Agency
- Hospice/Palliative Care Hospital
- Rehabilitation Services
- School of Nursing
- School of Radiography
- Sports Medicine Services
- Surgical Services
- Transitional Care Unit
- Women's Center

Facility Locations
 Sharon
 Hermitage
 Mercer
 Greenville
 Brookfield, OH

Main Campus
 740 East State Street
 Sharon, PA 16146-3395
 724-983-3911
 www.sharonregional.com

John A. Zidarsek
 President & CEO

February 15, 2007

U.S. Nuclear Regulatory Commission
 Materials Licensing Branch
 Region 1
 475 Allendale Road
 King of Prussia, Pennsylvania 19406

K-3

03013670

RE: Materials License #37-01626-04
 Sharon Regional Health System

Dear Sir or Madam,

We respectfully request the removal of the following physicians from our license:

- Steven P. Karr, M.D.
- Adele Lipari, D.O.
- Barry E. Marchetto, M.D.
- Harish Panicker, M.D.

We wish to add the following as authorized users for privileges under 10 CFR 35 parts 100, 200, 300 and 500:

- Shanteri U. Nayak, M.D.
- Jonathan Potts, M.D.

Both Dr. Nayak and Dr. Potts are on the NRC License # 37-01317-01 at Allegheny General Hospital in Pittsburgh, Pennsylvania and are authorized for parts 35.100, 35.200, and 35.300.

We also wish to add Frederick Borts, M.D. as an authorized user for 10 CFR 35.100, 35.200. Dr. Borts is on NRC License # 53-30546 at Kaiser Permanente Medical Center in Honolulu, Hawaii.

If you have any questions or require additional information, please do not hesitate to contact the undersigned.

Sincerely,

John R. Janoso, Jr.
 Vice President/Chief Information Officer

JoAnne Esposito, B.A., R.T.R.
 Director of Medical Imaging

140024

NMSS/RGN MATERIALS-002

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grants Akash Sharma, M.D. Authorized User status under NRC license 37-01317-01 and PA license PA-0031 and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

1. Akash Sharma, M.D.
Authorized User

2. 67
Permit Number

3. Nuclear Medicine
Department or Section

4. October 5, 2004
Approval Date

5. Human Use Isotope Group

35.100 35.200 35.300 35.400 35.500 35.600
 35.1000 (ENDOVASCULAR THERAPY) depleted U-235 shielding

6. Authorized Use

Group I Group II Group III

Group I isotopes (high radiotoxicity): beta \geq 300 keV E_{γ} ; gamma \geq 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{γ} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group III isotopes (low radiotoxicity): beta < 100 keV E_{γ} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

7. Restrictions: NONE

Approval Signatures:

John Rehder, M.D. 10/5/04
John Rehder, M.D. Date
Chairman, Radiation Safety Committee
Allegheny General Hospital

Joseph G. Och, M.S. 10/5/04
Joseph G. Och, M.S. Date
Radiation Safety Officer
Allegheny General Hospital

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grants Shanteri U. Nayak, M.D. Authorized User status and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties* Form, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212 or 3290 William Pitt Way, Building 9, Pittsburgh, PA 15238. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

- 1. Shanteri U. Nayak, M.D.
Authorized User
- 2. 38
Permit Number
- 3. Nuclear Medicine
Department or Section
- 4. April 17, 2001
Approval Date
- 5. Human Use - Isotope Groups 35.100, 35.200, 35.300
Authorized Use

6. Group III Group II Group I

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group I isotopes (high radiotoxicity): beta \geq 300 keV E_{avg} ; gamma \geq 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Approval Signatures:

Gilbert Isaacs
Gilbert Isaacs, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

4/17/01
Date

Joseph G. Och
Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

4/17/01
Date

ALLEGHENY GENERAL HOSPITAL RADIOACTIVE MATERIAL USE PERMIT

This permit grants Jonathan Potts, M.D. Authorized User status and is authorized to receive, possess, transfer, and ship radioactive material of the type(s) listed below. The Authorized User is expected to comply with 1) the *Authorized User Responsibilities and Duties Form*, 2) applicable sections from Title 10, Code of Federal Regulations, 3) applicable sections from Title 25, Pennsylvania Code, and 4) any additional requirements mandated by the Radiation Safety Committee. Radioactive isotopes stated below may only be used at 320 East North Ave., Pittsburgh, PA 15212 or 3290 William Pitt Way, Building 9, Pittsburgh, PA 15238. Any reason to use or transfer radioactive material to a location other than those listed must be approved by the Radiation Safety Committee.

- 1. Jonathan Potts, M.D.
Authorized User
- 2. 38
Permit Number
- 3. Nuclear Medicine
Department or Section
- 4. January 17, 1997
Approval Date
- 5. Human Use - Isotope Groups 35.100, 35.200, 35.300
Authorized Use

6. Group III Group II Group I

Group III isotopes (low radiotoxicity): beta < 100 keV E_{avg} ; gamma < 100 keV
H-3, C-14, S-35, Ca-45, Ru-103

Group II isotopes (medium radiotoxicity): beta < 300 keV E_{avg} ; gamma < 300 keV
Cr-51, Co-57, Tc-99m, I-123, I-125, Xe-133, Ce-141, Tl-201

Group I isotopes (high radiotoxicity): beta \geq 300 keV E_{avg} ; gamma \geq 300 keV
P-32, Ga-67, Rb-86, Sr-89, I-131

Approval Signatures:

G. H. Isaacs
Gilbert Isaacs, M.D.
Chairman, Radiation Safety Committee
Allegheny General Hospital

8/2/00
Date

Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital

Date

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES
Amendment No. 64

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 83-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Kaiser Foundation Hospital Diagnostic Imaging Department</p> <p>2. 3288 Moanalua Road Honolulu, HI 96819</p>	<p>In accordance with letter dated September 1, 2004</p> <p>3. License number 53-05379-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date November 30, 2004</p> <hr/> <p>5. Docket No. 030-03548 Reference No.</p>
--	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. 3 curies (not to exceed 200 millicuries per container)
A. Iodine-125	D. Liquid as Iotrex™	D. As needed

9. Authorized use:
- A. Medical use described in 10 CFR 35.100.
 - B. Medical use described in 10 CFR 35.200.
 - C. Medical use described in 10 CFR 35.300.
 - D. For brachytherapy use in the Proxima Therapeutics' G1aSite® Radiotherapy system.

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 3288 Moanalua Road, Honolulu, Hawaii.
- 11. The Radiation Safety Officer for this license is Samuel Wu, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
53-05379-01

Docket or Reference Number
030-03546

Amendment No. 64

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Decha Intaraprasong, M.D.	35.100, 35.200, 35.300
Chung Ta Hsin, M.D.	35.100, 35.200, 35.300
Katrena U. Wade Kennedy, M.D.	35.100, 35.200
Rickie A. Broadfoot, M.D.	35.100, 35.200
Allson M. Shibuya, M.D.	35.100, 35.200, 35.300
Stein Rafto, M.D.	35.100, 35.200
Peter Abcarlan, M.D.	35.100, 35.200
Daniel C. Henshaw, M.D.	35.100, 35.200, 35.300
Bradford S. Burton, M.D.	35.100, 35.200
Frederick T. Borts, M.D.	35.100, 35.200
Felix Lee Song, M.D.	35.100, 35.200
Ramana B. Muthyala, M.D.	35.100, 35.200
Marle S. Noltakis, M.D.	35.100, 35.200
Samuel M. H. Wu, M.D.	35.100, 35.200, 35.300
John T. Watabe, M.D.	35.100, 35.200
Vincent Brown, M.D.	I-125
Paul DeMare, M.D.	I-125
Thanh Huynh, M.D.	I-125
Christina Liu, M.D.	I-125
Thomas G. Mahon, M.D.	35.100, 35.200
Steven W. Hong, M.D.	35.100, 35.200, 35.300

13. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.
- B. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source received from another person shall not be put into use until tested.
- C. Sealed sources need not be leak tested if:
- (i) they contain only hydrogen-3; or
 - (ii) they contain only a radioactive gas; or
 - (iii) the half-life of the isotope is 30 days or less; or
 - (iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 4 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
53-05379-01Docket or Reference Number
030-03546

Amendment No. 64

- (v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- D. The leak test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region IV, ATTN: Director, Division of Nuclear Materials Safety, 611 Ryan Plaza Drive, Suite 400, Arlington, Texas 76011-8064. The report shall specify the source involved, the test results, and corrective action taken.
- E. The licensee is authorized to collect leak test samples for analysis by Health Physics Northwest. Alternatively, tests for leakage and/or contamination may be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.
14. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.
15. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
16. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
17. Notwithstanding the requirements in 10 CFR 35.400, the licensee may use Iodine-125 in the form of Iotrex™ liquid brachytherapy source in the Proxima Therapeutics' GIIaSite® Radiotherapy system.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
53-05379-01

Docket or Reference Number
030-03546

Amendment No. 64

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Letter dated May 25, 1994
- B. Facsimile dated November 28, 1994
- C. Letter dated December 16, 1994
- D. Letter dated June 8, 1995
- E. Letter dated March 21, 1996
- F. Letter dated April 25, 1996
- G. Letter dated May 6, 1996
- H. Letter dated July 1, 1996
- I. Letter dated March 13, 1997
- J. Letter dated June 8, 1998
- K. Letter dated December 28, 1998
- L. Letter dated July 5, 2001
- M. Letter dated June 10, 2002
- N. Letter dated April 11, 2003
- O. Letter dated July 3, 2003
- P. Letter dated November 20, 2003

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 23, 2004

By: *Rachel S. Browder*
 Rachel S. Browder, Health Physicist
 Nuclear Materials Licensing Branch
 Region IV
 Arlington, Texas 76011